Family Medicine Doctors in Tulsa, OK Accepting Medicare

376 Family Medicine doctors found. Showing 61 - 80

Chandan Lad, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3218 S 79th East Ave, Tulsa, OK 74145 Phone: 918-728-6880    Fax: 918-728-6881

Kyle Travis Jones, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 7600 S Lewis Ave, Tulsa, OK 74136 Phone: 918-493-7800

Zachary Alan Fowler, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1717 S Utica Ave Ste A, Tulsa, OK 74104 Phone: 918-748-7557    Fax: 918-748-7514

Kristin Lee Browning, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 14002 E 21st St Ste 1130, Tulsa, OK 74134 Phone: 918-439-1500    Fax: 918-439-1199

Dr. Abel L Lau, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 5323 S 65th West Ave, Tulsa, OK 74107 Phone: 918-340-5400

Adam Benjamin Greer, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 8115 S Memorial Dr, Tulsa, OK 74133 Phone: 918-254-6315    Fax: 918-403-6315

Renee Frenier, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 8414 E 101st St, Tulsa, OK 74133 Phone: 918-369-3200

Brian K Berryman, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 7912 E 31st Ct Ste 200, Tulsa, OK 74145 Phone: 918-743-8200    Fax: 918-743-8609

Amanda Dayle Carey, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2345 Southwest Blvd, Tulsa, OK 74107 Phone: 918-582-1980

Dr. Cameron C Henderson, D.O. Family Medicine Medicare: Medicare Enrolled Practice Location: 2345 Southwest Blvd, Tulsa, OK 74107 Phone: 918-561-1131

Colin Jeffrey Morgan, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 6585 S Yale Ave Ste 1220, Tulsa, OK 74136 Phone: 918-502-4950    Fax: 918-502-4955

Amanda Rene Reed, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 10109 E 79th St, Tulsa, OK 74133 Phone: 918-233-9550

Dr. Jim B Harjo, D.O. Family Medicine Medicare: Medicare Enrolled Practice Location: 3840 S 103rd East Ave Ste 100, Tulsa, OK 74146 Phone: 918-921-9700    Fax: 918-292-8263

Dr. Bryan Kent Ledbetter, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 11106 S Yale Ave Ste 100, Tulsa, OK 74137 Phone: 918-895-7000    Fax: 918-895-7213

Zoe L Smothermon, D.O. Family Medicine Medicare: Medicare Enrolled Practice Location: 1717 S Utica Ave Ste A, Tulsa, OK 74104 Phone: 918-748-7557

Babitha Vargis Kallimel, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 7600 S Lewis Ave, Tulsa, OK 74136 Phone: 918-493-7800    Fax: 918-493-7888

Eva K Earls, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1831 E 71st St, Tulsa, OK 74136 Phone: 877-866-7123

T Jeffrey Emel, MD Family Medicine - Sports Medicine Medicare: Medicare Enrolled Practice Location: 6475 S Yale Ave Ste 301, Tulsa, OK 74136 Phone: 918-494-9300    Fax: 918-494-9355

Joan E Stewart, DO Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 2345 Southwest Blvd, Tulsa, OK 74107 Phone: 918-561-8395    Fax: 918-561-8525

Dr. Kevin Andrew Jones, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 9001 S 101st East Ave Ste 270, Tulsa, OK 74133 Phone: 918-392-7200

News Archive

Furiex acquires full rights to JNJ-Q2, a novel broad-spectrum fluoroquinolone antibiotic

Furiex Pharmaceuticals, Inc. announced today that it has acquired full exclusive license rights to develop and commercialize the compound JNJ-Q2 under its existing development and license agreement with Janssen Pharmaceutica N.V.. Furiex acquired these rights as a result of Janssen's decision not to exercise its option under the agreement that gave Janssen the opportunity to continue development of JNJ-Q2.

SCYNEXIS receives four grants under QTDP program to develop cyclophilin inhibitors

Drug discovery and development company SCYNEXIS, Inc. today announced that the Company has been awarded four grants totaling $977,917 under the U.S. Federal Government's Qualifying Therapeutic Discovery Project (QTDP). SCYNEXIS is developing a proprietary internal pipeline of cyclophilin inhibitors, a class of drugs that hold significant potential for the treatment of a broad range of diseases.

Securin is not required for chromosomal stability in human cells

A critical aspect of cell division, or mitosis, is that the progeny cells must receive the full complement of chromosomes.

New trial confirms superiority of triplet regimen over standard care in resectable esophago-gastric cancer

The superiority of docetaxel based triplet therapy over standard care in patients with resectable oesophago-gastric cancer has been confirmed in late-breaking results from the FLOT4 trial presented at the ESMO 2017 Congress in Madrid.

Reversible cell-specific drug delivery with aptamer-functionalized liposomes

For cancer drug developers, finding an agent that kills tumor cells is only part of the equation. The drug also must spare healthy cells, and ideally its effects will be reversible to cut short any potentially dangerous side effects. Investigators from the University of Illinois at Urbana-Champaign report that they have assembled a new cancer drug delivery system that, in cell culture, achieves all of the above.

Read more Medical News

› Verified 3 days ago

• 1
• 2
• 3
• 4(current)
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• »